Emma Watz1,2, Mats Remberger1,3, Olle Ringden1,3, Per Ljungman4,5, Mikael Sundin6,7, Jonas Mattsson1,3, Michael Uhlin1,3,2. 1. Department of Oncology and Pathology. 2. Department of Clinical Immunology and Transfusion Medicine. 3. Centre for Allogeneic Stem Cell Transplantation. 4. Department of Hematology. 5. Division of Hematology, Department of Medicine, Huddinge. 6. Hematology/Immunology/SCT Section, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden. 7. Division of Pediatrics, Department of Clinical, Science, Intervention and Technology, Karolinska Institutet.
Abstract
BACKGROUND: In approximately two-thirds of patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) no suitable related donor can be identified but an unrelated HLA-matched donor can be found through international donor registries. HSCT grafts from unrelated donors are commonly collected at distant sites. Therefore, graft storage and transportation becomes crucial in the HSCT process. We aimed to study the impact of graft quality on clinical outcome and identify factors affecting graft quality. STUDY DESIGN AND METHODS: We investigated the influence of graft quality on the clinical outcome in 144 HSCT patients. Graft quality was assessed by determining the viability (7-aminoactinomycin D [7AAD]) on a frozen-thawed sample from the peripheral blood stem cell (PBSC) graft. RESULTS: Patients receiving PBSCs with inferior quality (i.e., viability < 64% in the frozen-thawed sample) more frequently developed acute graft-versus-host disease (aGVHD) Grades I to IV than patients receiving grafts with better quality (p = 0.025). The transplant-related mortality (TRM) was higher in the group receiving grafts with lower viability (p = 0.03). The viability of the frozen-thawed samples was highly variable (median, 64%; range, 24%-96%). No correlation could be observed when comparing the viability in newly arrived PBSC grafts to frozen-thawed vials. Grafts with white blood cell (WBC) count of more than 300 × 10(9) /L had lower viability than those with lower WBC counts (p < 0.001). CONCLUSION: Graft quality affects clinical outcome. Patients receiving grafts with inferior quality had more aGVHD and higher TRM. There is a need for better analyses for assessing graft quality in routine HSCT care; analysis using 7AAD on fresh PBSC grafts is not sufficient.
BACKGROUND: In approximately two-thirds of patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) no suitable related donor can be identified but an unrelated HLA-matched donor can be found through international donor registries. HSCT grafts from unrelated donors are commonly collected at distant sites. Therefore, graft storage and transportation becomes crucial in the HSCT process. We aimed to study the impact of graft quality on clinical outcome and identify factors affecting graft quality. STUDY DESIGN AND METHODS: We investigated the influence of graft quality on the clinical outcome in 144 HSCT patients. Graft quality was assessed by determining the viability (7-aminoactinomycin D [7AAD]) on a frozen-thawed sample from the peripheral blood stem cell (PBSC) graft. RESULTS:Patients receiving PBSCs with inferior quality (i.e., viability < 64% in the frozen-thawed sample) more frequently developed acute graft-versus-host disease (aGVHD) Grades I to IV than patients receiving grafts with better quality (p = 0.025). The transplant-related mortality (TRM) was higher in the group receiving grafts with lower viability (p = 0.03). The viability of the frozen-thawed samples was highly variable (median, 64%; range, 24%-96%). No correlation could be observed when comparing the viability in newly arrived PBSC grafts to frozen-thawed vials. Grafts with white blood cell (WBC) count of more than 300 × 10(9) /L had lower viability than those with lower WBC counts (p < 0.001). CONCLUSION: Graft quality affects clinical outcome. Patients receiving grafts with inferior quality had more aGVHD and higher TRM. There is a need for better analyses for assessing graft quality in routine HSCT care; analysis using 7AAD on fresh PBSC grafts is not sufficient.
Authors: Laura F Newell; Kelsea M Shoop; Rebekah J Knight; Sara N Murray; Rogelyn P Kwock; Carol E Jacoby; Susan Slater; Bryon E Allen; Casondra Ottowa; Brad Cota; Peggy L Appel; Rachel J Cook; Richard T Maziarz; Gabrielle Meyers Journal: Cytotherapy Date: 2019-05-10 Impact factor: 5.414
Authors: Hao Zhou; Lisa Nguyen; Cosimo Arnesano; Yuta Ando; Manmeet Raval; Joseph T Rodgers; Scott Fraser; Rong Lu; Keyue Shen Journal: iScience Date: 2020-01-10